- Home
- MDGL
as 07-11-2025 3:35pm EST
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 6.1B | IPO Year: | N/A |
| Target Price: | $420.63 | AVG Volume (30 days): | 282.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -17.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $200.63 - $377.46 | Next Earning Date: | 08-06-2025 |
| Revenue: | $317,383,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 286.17% | Revenue Growth (next year): | 64.17% |
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
Insider Monkey
18 days ago
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra
Pharmaceutical Technology
22 days ago
Madrigal poised to enter European MASH market after CHMP endorsement
MT Newswires
22 days ago
Sector Update: Health Care Stocks Rise Premarket Friday
MT Newswires
22 days ago
Exchange-Traded Funds Slightly Higher, Equity Futures Mixed Pre-Bell Friday as Geopolitical, Trade Risks Mount
MT Newswires
22 days ago
Madrigal Gets Positive Opinion From EMA for Resmetirom to Treat Liver Disease
GlobeNewswire
22 days ago
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
GlobeNewswire
24 days ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
Exploring High Growth Tech Stocks In The US Market
Compare MDGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.